

# Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis

Edward K. Thomsen,<sup>1,2,a</sup> Nelly Sanuku,<sup>1</sup> Manasseh Baea,<sup>1</sup> Samson Satofan,<sup>1</sup> Elit Maki,<sup>1</sup> Bart Lombore,<sup>1</sup> Mark S. Schmidt,<sup>3</sup> Peter M. Siba,<sup>1</sup> Gary J. Weil,<sup>4</sup> James W. Kazura,<sup>2</sup> Lawrence L. Fleckenstein,<sup>3</sup> and Christopher L. King<sup>2,5</sup>

<sup>1</sup>Papua New Guinea Institute of Medical Research, Papua New Guinea; <sup>2</sup>Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio; <sup>3</sup>Department of Pharmaceutical Sciences & Experimental Therapeutics, University of Iowa, Iowa City; <sup>4</sup>Department of Medicine, Infectious Diseases Division, Washington University School of Medicine, St. Louis, Missouri; and <sup>5</sup>Veterans Affairs Medical Center, Cleveland, Ohio

**Background.** Available treatments for lymphatic filariasis (LF) are limited in their longterm clearance of microfilaria from the blood. The safety and efficacy of a single-dose triple-drug therapy of the antifilarial drugs diethylcarbamazine (DEC), ivermectin (IVM), and albendazole (ALB) for LF are unknown.

**Methods.** We performed a pilot study to test the efficacy, safety, and pharmacokinetics of single-dose DEC, IVM, and ALB in *Wuchereria bancrofti*-infected Papua New Guineans. Adults were randomized into 2 treatment arms, DEC 6 mg/kg + ALB 400 mg (N = 12) or DEC 6 mg/kg + ALB 400 mg + IVM 200 µg/kg (N = 12), and monitored for microfilaria, parasite antigenemia, adverse events (AEs), and serum drug levels.

**Results.** Triple-drug therapy induced >2-log reductions in microfilaria levels at 36 and 168 hours after treatment compared with approximately 1-log reduction with 2 drugs. All 12 individuals who received 3 drugs were microfilaria negative 1 year after treatment, whereas 11 of 12 individuals in the 2-drug regimen were microfilaria positive. In 6 participants followed 2 years after treatment, those who received 3 drugs remained microfilaria negative. AEs, particularly fever, myalgias, pruritus, and proteinuria/hematuria, occurred in 83% vs 50% of those receiving triple-drug compared to 2-drug treatment respectively ( $P = .021$ ); all resolved within 7 days after treatment. No serious AEs were observed in either group. There was no significant effect of IVM on DEC or ALB drug levels.

**Conclusions.** Triple-drug therapy is safe and more effective than DEC + ALB for Bancroftian filariasis and has the potential to accelerate elimination of lymphatic filariasis.

**Keywords.** lymphatic filariasis; chemotherapy; diethylcarbamazine; albendazole; ivermectin.

*Wuchereria bancrofti* is a mosquito-transmitted, chronically disabling nematode infection that causes lymphedema, elephantiasis, and hydroceles. *Wuchereria bancrofti* is endemic in 73 countries, infecting approximately 100 million people [1]. The World Health Organization has targeted lymphatic filariasis (LF) for global elimination by 2020 [2]. Since there is no drug that reliably kills or sterilizes adult filarial worms, the focus of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) has been on the use of mass drug administration (MDA) to reduce the source of microfilaria in endemic populations and thereby interrupt transmission. The current MDA strategy is to provide repeated, annual doses of albendazole (ALB) with either diethylcarbamazine (DEC) or ivermectin (IVM) for the lifespan of adult worms (typically 5–7 years)

[3]. Mathematical models of LF transmission suggest that the most potent drug combination currently recommended (annual DEC + ALB) will require high compliance (>70%) with MDA for 5–7 years in order to achieve elimination targets, particularly in areas with moderate to high endemicity [4]. Clinical trials have shown that a single dose of this combination clears microfilaria in only approximately 25% of participants at 12 months [5–8]. Drug regimens with better activity against microfilaria would prevent new infections that would otherwise have to be treated in later years. This could significantly improve the chances for eliminating LF in resource poor settings.

Addition of the potent microfilaricide IVM to DEC + ALB may improve microfilaria clearance and provide a more long-lasting effect than the widely used 2-drug regimen [7–9]. Prior community studies have shown that MDA with IVM plus DEC was more effective for reducing microfilaria rates than DEC alone [10]. A single dose of IVM completely cleared microfilaria in 35% of participants and reduced the geometric mean microfilaria level by >98% at 1 year; 2 years after a single treatment, 20% of participants remained microfilaria negative, and geometric mean microfilaria levels remained reduced by >90% [11]. Similar but less profound


Received 20 June 2015; accepted 7 October 2015.

<sup>a</sup>E. K. T. is currently at the Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

Correspondence: C. L. King, 10900 Euclid Ave, Rm 421, Biomedical Research Bldg, Cleveland, OH 44106 (cxk21@case.edu).

Clinical Infectious Diseases®

© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com. DOI: 10.1093/cid/civ882



**Figure 1.** Study design. Abbreviations: ALB, albendazole; ALT, alanine transaminase; AST, aspartate transaminase; BP, blood pressure; Cr, creatinine; DEC, diethylcarbamazine; F, female; Hgb, hemoglobin; hx, history; IV, intravenous; IVM, ivermectin; LF, lymphatic filariasis; M, male; mf, microfilaria; NL, normal; PE, physical examination; U/A, urinalysis.

effects were observed for single-dose IVM in a trial conducted in Tanzania [12]. It is possible that simultaneous treatment with IVM + DEC + ALB could reduce the number of rounds of MDA required to reach LF elimination, and this could have a transformative impact on the 60% of LF-exposed populations that reside outside of sub-Saharan Africa.

Since the tolerability and potential drug interactions of this 3-drug combination have never been investigated, we undertook a pilot study to compare the safety, tolerability, pharmacokinetics, and efficacy of IVM + DEC + ALB vs DEC + ALB in individuals with Bancroftian filariasis.

## METHODS

### Study Location

Participants were recruited from the villages of Tau 1 and 2 (3.6718 S, 142.7254 E), Dreikikir District, in East Sepik Province, Papua New Guinea, with microfilaria rates of 10%–44%. No prior

treatment for LF has ever been given in these 2 communities. All participants were hospitalized at the Dreikikir Health Center for the initial days following treatment.

### Selection of Study Participants and Study Design

Study inclusion and exclusion criteria were as follows: aged 18–60 years, >100 microfilaria /mL, no prior antifilarial medications, or free from any acute or chronic illnesses. If inclusion and exclusion criteria were fulfilled, enrolled individuals had a 1-mL venous night blood sample (after 2200 hours) and serum biochemistries measured to ensure that alanine transaminase (ALT), aspartate transaminase (AST), and creatinine were <1.5 times normal; hemoglobin levels were >7 gm/dL; and there was no significant urine proteinuria, hematuria, or glucosuria by dipstick measurement 1 to 2 weeks prior to hospitalization (Figure 1). A total of 903 individuals were prescreened, 53 were enrolled, and 24 met the final inclusion and exclusion

criteria and agreed to participate in the study. One individual withdrew 72 hours after treatment and 2 individuals failed to return on day 7 but did have blood drawn 1 year later. Eleven individuals were unavailable at the 2-year follow-up (Figure 1). This was a single-blinded, parallel-group, randomized study with 2 treatment arms. Participants were stratified by sex and randomly assigned to 1 of 2 treatment groups: DEC 6 mg/kg + ALB 400 mg or DEC 6 mg/kg + IVM 200 µg/kg + ALB 400 mg. A blood sample was taken to establish baseline ALT, AST, and creatinine levels immediately prior to treatment. Participants were given a breakfast of peanut butter and biscuits prior to observed administration of drugs. Blood draws were performed at 0, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours and 7 days following experimental drug treatment (Figure 1).

#### Parasitological, Biochemical, and Drug Testing

Parasitemia levels were assessed by passing 1 mL of anticoagulated, nocturnally collected blood through a 5-µm polycarbonate filter (EMD Millipore Corp., Billerica, Massachusetts), washed with filtered water, placed on glass slides, dried, and stained with Giemsa. Microfilariae were counted by microscopy. Antigen levels were measured using the Og4C3 mAb-based assay [13]. Plasma for drug levels was stored at -80°C. Evaluation of AST, ALT, and creatinine levels was performed using a Vitros DT-60 II biochemistry analyzer (Ortho Clinical Diagnostics, Rochester, New York). Glucose, blood, protein, nitrites, and leukocytes were measured with a urine dipstick (Multistix 10 SG, Bayer/Seimens, Malvern, Pennsylvania), with severity graded according to the manufacturer's protocol. Hemoglobin levels were evaluated on a HemoCue Hb 201+ machine (HemoCue Inc. Cypress, California).

All pharmacokinetic analyses were performed at the University of Iowa's College of Pharmacy. The concentration of DEC was determined using high-performance liquid chromatography with mass spectrometric detection [14]. IVM concentrations were determined using a previously published extraction methodology [15]. The linear range of the calibration curve was 0.20–400 ng/mL from 0.20 mL plasma.

#### Clinical Evaluation and Adverse Events Recording

The night prior to drug dosing, a thorough clinical assessment was performed. Circumference of all limbs was recorded at each time point. Scrotal abnormalities were classified as edema, hernia, or hydrocele, and any hydroceles graded as smaller or larger than a fist.

Objective adverse events (AEs) were based on serial physical examinations, biochemical evaluations, and urinalysis every 4 hours for the first 12 hours then at 24, 48, and 72 hours and 7 days after treatment (Figure 1). AEs were defined as any one of the following: any increase in ALT, AST, or creatinine measurement >1.5 times the upper limit of the reference range; tympanic temperature >37.8°C; increase in lymph node tenderness, swelling, or pain from baseline; or increase in proteinuria or hematuria from baseline based on urine dipstick

measurement. A scoring system was used for proteinuria and hematuria based on severity and duration of the abnormal dipstick measurement. First hematuria (or proteinuria) was scored as negative (0), mild (1+), moderate (2+), and severe (3+) with a negative assigned a score of 0, mild a score of 1, moderate a score of 2, and severe a score of 3. If an abnormal urine dipstick measurement was observed on just 1 testing day post-treatment (eg, at 24, 48, and 72 hours and day 7 post-treatment), a score of 1 was given. If the urine dipstick measurement remained abnormal for 2 days, a score of 2 was given to a maximum of 4 if the urinalysis remained abnormal for the 4 testing time points. A final score for each treatment group was determined by adding the sum of all these values for the 12 individuals in each group.

Subjective AEs were assessed by asking participants about symptoms that they may have experienced after taking the medication that either increased in severity or was experienced for the first time following treatment. Participants were asked to categorize any symptoms as mild (does not interfere with daily activity), moderate (interferes with daily activity), or severe (warrants hospital admission).

#### Informed Consent and Regulatory Monitoring

Institutional review boards at the University Hospitals Case Medical Center, Cleveland, Ohio, the Papua New Guinea Institute of Medical Research, and the Medical Research Advisory Committee of Papua New Guinea approved study protocols and documents. The trial was registered at ClinicalTrials.gov (NCT01975441).

#### Data Treatment and Analyses

The study was powered to look at drug interactions and AEs, with changes in microfilaria levels as a secondary outcome. Objective and subjective AEs were compared separately using Mann-Whitney-Wilcoxon rank sum test. Differences in microfilaremia levels were assessed using student *t* test of log-transformed data. A general linear model was used to examine the independent effects of treatment and microfilaremia levels on the frequency of AEs.

For each participant, pharmacokinetic parameters were estimated by plotting the plasma concentrations (of DEC, ALB, albendazole sulfoxide [ALBSO], albendazole sulfone [ALBSO<sub>2</sub>], or IVM) vs time using noncompartmental analysis (WinNonlin v5.0, Pharsight Corporation, Cary, North Carolina). The maximum plasma concentration ( $C_{max}$ ) and time of maximum concentration ( $T_{max}$ ) were observed directly from the concentration-time curve. The half-life, area under the curve, and drug-drug interactions were calculated as previously described [14–17] and are included in the [Supplementary Materials](#).

## RESULTS

#### Population Characteristics and Impact of Treatment on Infection Levels

Before treatment study participants in the 2 treatment groups had similar infection intensities, age, weight, and hemoglobin levels (Table 1). A single dose of DEC + ALB + IVM resulted

**Table 1. Population Characteristics and Pretreatment Infection Levels**


Treatment Group	N	Male/ Female	Geometric Mean Microfilaremia (microfilaria /mL) ± 95% CI (range)	Filarial Antigen (unit/mL) Geometric Mean ± 95% CI	Median Age, y (range)	Mean Weight, kg ± SD	Mean Hemoglobin, g/dL ± SD
Diethylcarbamazine + albendazole + ivermectin	12	6/6	1558 ± 2322 (209–13 776)	3881 ± 1227	30 (19–59)	53 ± 9	11.2 ± 1.3
Diethylcarbamazine + albendazole	12	6/6	1857 ± 2191 (133–13 333)	3347 ± 1018	28 (19–50)	49 ± 8	11.0 ± 1.2

Abbreviations: CI, confidence interval; SD, standard deviation.

in almost total elimination of microfilaria at 36 hours and 7 days after treatment, and no participant was microfilaremic 12 months after treatment (Figure 2). By contrast, a single dose of DEC + ALB resulted in less dramatic reductions in microfilaria levels at 36 hours and 7 days, and 10 of 11 participants remained microfilaremic at the 12-month time point. Twelve participants who had not moved away and agreed to have an additional night blood sample drawn (by chance, 6 in each treatment group) were examined for microfilaria levels 2 years following treatment (Table 2). All 6 individuals who received the single 3-drug treatment remained amicrofilaremic at 2 years ( $P = .047$ , compared with those receiving 2 drugs; Table 2). DEC + ALB + IVM also resulted in greater decreases in filarial antigen levels compared with DEC + ALB at 12 months (Figure 3). All participants in both treatment groups remained antigen positive at 12 months and at 2 years.

**Adverse Events Following Treatment**

Objective and subjective AEs were mild to moderate in severity and were experienced by participants in both treatment groups (Table 3). The first AEs started 4 hours after treatment, typically they were subjective findings such as nausea and headaches. These were usually followed by arthralgias and pruritus that often presented by 8 hours after treatment. Two participants also developed mild inguinal tenderness at that time. One individual developed a fever at 8 hours post-treatment. In other individuals that developed fevers following treatment, elevated temperatures were present by 12 hours post-treatment. Temperatures often exceeded 39°C and were successfully treated with acetaminophen. Seven individuals developed hematuria and/or proteinuria, 3 at 24 hours post-treatment and the remaining by 48 hours. Hematuria and/or proteinuria resolved by 72 hours in 3 of 7 individuals, and the remainder resolved by 7 days. Abnormal transaminases were confined to AST and followed a



**Figure 2.** Percent reduction in microfilaria compared to pretreatment levels at 36 hours, 7 days, and 1 year following treatment with diethylcarbamazine (DEC) + albendazole (ALB) + ivermectin (IVM) or DEC + ALB. Microfilaria levels were determined by filtering 1 mL of anticoagulated, nocturnally collected peripheral venous blood through a nucleopore filter. Significance determined by Student *t* test.

**Table 2. Microfilarial Levels 2 Years Following a Single Treatment**

Treatment	Time Post-Treatment				
	Pre-Treatment	36 h	7 d	1 y	2 y
Diethylcarbamazine + albendazole	3235 <sup>a</sup>	4	9	10	0
	1599	10	8	11	44
	1562	1	627	22	0
	1095	27	49	7	4
	1107	13	1	27	13
	1747	87	947	29	37
Diethylcarbamazine + albendazole + ivermectin	689	0	0	0	0
	677	1	1	0	0
	1034	6	8	0	0
	1476	1	4	0	0
	1857	0	0	0	0
	2509	0	0	0	0

<sup>a</sup> Microfilaria per milliliter of filtered whole blood.

similar kinetics of hematuria and/or proteinuria, with all resolving by 7 days after treatment.

Overall, 10 of 12 (83%) individuals in the 3-drug treatment group developed 1 or more objective AEs compared with 6 of 12 (50%,  $P = .19$ , Fischer exact test) in the 2-drug group. Median number of AEs per person in the 3-drug group was 2 compared with 0.5 in the 1-drug group ( $P = .094$ ). Hematuria and/or proteinuria also predominantly occurred in the 3-drug treatment

group. A scoring system was used based on severity and duration of the hematuria and/or proteinuria (see “Methods” section), with individuals in the 3-drug group having a score of 16 vs 1 in the 2-drug group.


With respect to subjective AEs, the proportion of individuals who developed 1 or more complaints, including headache, nausea, pruritus, abdominal pain, weakness, and arthralgia (Table 2), was similar between the 2 treatment groups (9 of 12 [75%] in the 3-drug group and 7 of 12 [58%] in the 2-drug group). Individuals in the 3-drug group tended to have more subjective AEs (median = 2.5) compared with those in the 2-drug group (median = 1,  $P = .091$ ).

When both subjective and objective AEs were combined, individuals on 3-drug therapy had significantly more AEs (median = 4.5) compared with those receiving 2-drug treatment (median = 2.5,  $P = .021$ ). Microfilaremia levels prior to treatment (or closely related reduction in microfilaria levels at 36 hours) were related to the number of AEs independent of treatment ( $P = .09$ ).

#### Drug Interactions and Pharmacokinetics

Drug concentration–time curves are shown in Figure 4 and Supplementary Figure 1. The pharmacokinetic parameter estimates for DEC, ALB, ALBSO, and ALBSO<sub>2</sub> with and without IVM administration are presented in Supplementary Table 1, along with parameter estimates for IVM. No significant drug interactions were observed ( $P > .05$  for all treatment group comparisons).

Geometric mean parameter ratios [(with IVM)/(without IVM)] of  $C_{max}$ ,  $AUC_{0-t}$ , and  $AUC_{0-\infty}$  for each analyte (DEC, ALBSO, and ALBSO<sub>2</sub>) are presented with 90% confidence intervals (CIs) in Supplementary Table 2. DEC  $C_{max}$  levels in the 2 treatment groups almost met the commonly used limits for no clinically relevant effect (80%–125%) [17–19]. DEC  $AUC_{0-t}$  and



**Figure 3.** Percent reduction in serum filarial antigen levels 1 year following treatment compared to levels before treatment in participants receiving a single dose of diethylcarbamazine (DEC) + albendazole (ALB) + ivermectin (IVM) or DEC + ALB. Antigen levels were measured using the Og4C3 assay. Significance determined by Student *t* test.

**Table 3. Number and Frequency of Adverse Events Experienced by Study Participants After Treatment**


Adverse Event	Regimen	
	Diethylcarbamazine + Albendazole (N = 12)	Diethylcarbamazine + Albendazole + Ivermectin (N = 12)
<b>Objective findings</b>		
Fever	2 (17)	6 (50)
Lymphadenitis	5 (42)	3 (25)
Hepatic (alanine transaminase \aspartate transaminase) abnormalities <sup>a</sup>	2 (17)	1 (8)
Proteinuria	1 (8)	3 (25)
Hematuria	0 (0)	4 (33)
Transient low blood pressure	1 (8)	1 (8)
<b>Subjective findings</b>		
Headache	3 (25)	6 (50)
Joint pain	5 (42)	7 (58)
Nausea	1 (8)	3 (25)
Cough	0 (0)	5 (42)
Abdominal pain	1 (8)	4 (33)
Itch	3 (25)	5 (42)
Weakness	0 (0)	2 (17)
Dizziness	2 (17)	1 (8)

<sup>a</sup> >1.5 times the upper limit of normal.

AUC<sub>0-∞</sub> 90% CIs obtained in this study were only slightly outside of these limits but were completely within the slightly less stringent limits of 70%–143%. Ninety percent CIs for the parameter estimates of ALBSO and ALBSO<sub>2</sub> were quite broad, because of the small samples sizes in this study.

**DISCUSSION**

In this study, we compared the effects of a new triple-drug regimen (IVM + DEC + ALB) with standard DEC + ALB as a single-dose treatment for Bancroftian filariasis in treatment-naive participants with high-intensity *W. bancrofti* infections. Triple therapy rapidly eliminated almost all microfilaria from peripheral blood, and, importantly, all participants treated with this regimen were amicrofilaremic 1 and 2 years following treatment. Microfilaria counts also rapidly declined in participants treated with DEC + ALB but less dramatically than in those treated with triple therapy. Also, the 2-drug therapy failed to clear microfilaria in most participants 12 and 24 months after treatment, which is consistent with results from other treatment trials [7–9, 11]. A greater reduction in circulating antigen levels with the triple-drug regimen suggests a higher percentage of adult female worms were killed compared with use of DEC + ALB. Since all treatment participants in both groups had persistently positive filarial antigen tests 1 and 2 years after treatment, neither treatment killed all adults worms [20]. The absence of microfilaria at 1 and 2 years after treatment suggests



**Figure 4.** Mean serum plasma levels (± standard deviation) of (A) diethylcarbamazine (DEC), (B) albendazole (ALB) sulfoxide and (C) ivermectin (IVM) at different times following treatment with DEC + ALB + IVM or DEC + ALB.

the triple-drug therapy had embryostatic and/or embryocidal effects on adult female worms.

Participants treated with the triple-drug regimen experienced more AEs than those who received DEC + ALB when both

objective and subjective AEs were combined. All AEs were mild to moderate in severity, started 8 hours following treatment, peaked at between 12 and 48 hours, and resolved 7 days later, except in 1 participant who had right inguinal tenderness at day 7. AEs observed were consistent with the well-documented transient AEs that have been reported following treatments that kill microfilaria [7–9]. These AEs include fever, headache, pruritus, arthralgia, tender lymph nodes, and development of proteinuria and/or hemoglobinuria. The spectrum of AEs was similar in the 2 treatment arms, except for urinary abnormalities, which were present almost exclusively in the 3-drug treatment group. Development of proteinuria and/or hemoglobinuria in urine ranged from mild to major, as measured by dipstick, and often persisted for several days. All urine abnormalities resolved by 7 days following treatment. No participant had a significant increase in serum creatinine after treatment. Transient urinary abnormalities were similar to those observed in a previous study following treatment with DEC alone [21]. The proteinuria and/or hemoglobinuria may arise from inflammation due to dead microfilaria in the kidney. Alternatively, participants may develop a transient immune complex associated glomerulonephritis, as based on prior studies in animal models of filariasis [22], renal histology [23–26], and presence of filariasis-specific immune complexes in blood and urine [27] of participants with LF.

Pharmacokinetic studies were performed to determine whether IVM affects drug levels or clearance of DEC and ALB. The absorption and disposition profiles of each drug (and/or ALB metabolites) were not significantly different in participants who received IVM. The pharmacokinetics of DEC and IVM were similar to those seen in previous studies [19, 28, 29]. The pharmacokinetics of ALB in this study was also consistent with that seen in prior studies that reported that ALB is poorly absorbed and rapidly eliminated, primarily through metabolism to ALBSO and ALBSO<sub>2</sub> [19, 28, 29]. The wide variation in ALBSO levels after ALB is well known and likely due to differences in absorption of the drug between individuals and differences in ALB metabolism between men and women [30]. There was a clear lack of significant interaction between DEC and IVM. Because of high interpatient variability in ALBSO exposure parameters, definitive conclusions cannot be drawn regarding the lack of an effect of IVM on ALBSO exposure. However, the point estimates for the ratios of geometric means are not suggestive of a major influence of IVM on ALBSO exposure, and in a previous analysis, Awadzi et al [28] failed to detect any substantial interaction between these drugs. Thus, it is unlikely that coadministration of IVM has a clinically significant drug interaction with ALB/ALBSO. It has historically been assumed that the minor metabolite ALBSO<sub>2</sub> is inactive against filarial parasites because of its relatively lower abundance in human serum compared with ALBSO and because of the known activity of ALB and ALBSO as antagonists of microtubule formation in nematodes [31]. However, a recent study

reported that ALBSO<sub>2</sub> prevents binary fission in *Wolbachia*, an obligate endosymbiont of *W. bancrofti* [32]. The present analysis is the first to quantify ALBSO<sub>2</sub> pharmacokinetics in patients with *W. bancrofti* infection.

This study has shown that single-dose treatment with IVM + DEC + ALB is safe and more effective for clearing *W. bancrofti* microfilaria and reducing filarial antigen levels than standard treatment with DEC + ALB. Additional studies are needed to determine the duration of microfilaria clearance after IVM + DEC + ALB and to further establish the safety of this regimen. A “one and done” regimen could have a transformative impact on the global program to eliminate LF by reducing the number of rounds of MDA required to reach elimination targets. This would be especially useful for countries such as Papua New Guinea where it is extremely difficult to provide repeated rounds of MDA to LF-endemic populations, and it could improve chances for global elimination of LF by the target year of 2020.

### Supplementary Data

Supplementary materials are available at <http://cid.oxfordjournals.org>. Consisting of data provided by the author to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the author, so questions or comments should be addressed to the author.

### Notes

**Financial support.** The Bill and Melinda Gates Foundation and Veterans Affairs Research Service supported this work.

**Potential conflicts of interest.** All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

### References

1. Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. *Lancet* 2010; 376:1175–85.
2. Ottesen EA, Hooper PJ, Bradley M, Biswas G. The global programme to eliminate lymphatic filariasis: health impact after 8 years. *PLoS Negl Trop Dis* 2008; 2:e317.
3. Tisch DJ, Michael E, Kazura JW. Mass chemotherapy options to control lymphatic filariasis: a systematic review. *Lancet Infect Dis* 2005; 5:514–23.
4. Michael E, Malecela-Lazaro MN, Kazura JW. Epidemiological modelling for monitoring and evaluation of lymphatic filariasis control. *Adv Parasitol* 2007; 65:191–237.
5. Bockarie MJ, Tavul L, Ibam I, et al. Efficacy of single-dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against *Wuchereria bancrofti* infection in Papua New Guinea. *Am J Trop Med Hyg* 2007; 76:62–6.
6. Farid HA, Hammad RE, Hassan MM, Ramzy RM, El Setouhy M, Weil GJ. Effects of combined diethylcarbamazine and albendazole treatment of bancroftian filariasis on parasite uptake and development in *Culex pipiens* L. *Am J Trop Med Hyg* 2005; 73:108–14.
7. Ismail MM, Jayakody RL, Weil GJ, et al. Long-term efficacy of single-dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. *Trans R Soc Trop Med Hyg* 2001; 95:332–5.
8. Ismail MM, Jayakody RL, Weil GJ, et al. Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. *Trans R Soc Trop Med Hyg* 1998; 92:94–7.
9. Ismail MM, Jayakody RL. Efficacy of albendazole and its combinations with ivermectin or diethylcarbamazine (DEC) in the treatment of *Trichuris trichiura* infections in Sri Lanka. *Ann Trop Med Parasitol* 1999; 93:501–4.
10. Bockarie MJ, Tisch DJ, Kastens W, et al. Mass treatment to eliminate filariasis in Papua New Guinea. *N Engl J Med* 2002; 347:1841–8.
11. Subramanyam Reddy G, Vengatesvarlou N, Das PK, et al. Tolerability and efficacy of single-dose diethyl carbamazine (DEC) or ivermectin in the clearance of

- Wuchereria bancrofti* microfilaraemia in Pondicherry, south India. *Trop Med Int Health* **2000**; 5:779–85.
12. Simonsen PE, Magesa SM, Dunyo SK, Malecela-Lazaro MN, Michael E. The effect of single dose ivermectin alone or in combination with albendazole on *Wuchereria bancrofti* infection in primary school children in Tanzania. *Trans R Soc Trop Med Hyg* **2004**; 98:462–72.
  13. More SJ, Copeman DB. A highly specific and sensitive monoclonal antibody-based ELISA for the detection of circulating antigen in bancroftian filariasis. *Trop Med Parasitol* **1990**; 41:403–6.
  14. Schmidt MS, King CL, Thomsen EK, Siba PM, Sanuku N, Fleckenstein L. Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies. *J Pharm Biomed Anal* **2014**; 98:307–10.
  15. Kitzman D, Wei SY, Fleckenstein L. Liquid chromatographic assay of ivermectin in human plasma for application to clinical pharmacokinetic studies. *J Pharm Biomed Anal* **2006**; 40:1013–20.
  16. Kitzman D, Cheng KJ, Fleckenstein L. HPLC assay for albendazole and metabolites in human plasma for clinical pharmacokinetic studies. *J Pharm Biomed Anal* **2002**; 30:801–13.
  17. Miller JR Jr, Fleckenstein L. Gas chromatographic assay of diethylcarbamazine in human plasma for application to clinical pharmacokinetic studies. *J Pharm Biomed Anal* **2001**; 26:665–74.
  18. Kshirsagar NA, Gogtay NJ, Garg BS, et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co-administration in a field study in an area endemic for lymphatic filariasis in India. *Trans R Soc Trop Med Hyg* **2004**; 98:205–17.
  19. Shenoy RK, Suma TK, John A, et al. The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole. *Ann Trop Med Parasitol* **2002**; 96:603–14.
  20. Chanteau S, Moulia-Pelat JP, Glaziou P, et al. Og4C3 circulating antigen: a marker of infection and adult worm burden in *Wuchereria bancrofti* filariasis. *J Infect Dis* **1994**; 170:247–50.
  21. Dreyer G, Ottesen EA, Galdino E, et al. Renal abnormalities in microfilaremic patients with Bancroftian filariasis. *Am J Trop Med Hyg* **1992**; 46:745–51.
  22. Klei TR, Crowell WA, Thompson PE. Ultrastructural glomerular changes associated with filariasis. *Am J Trop Med Hyg* **1974**; 23:608–18.
  23. Date A, Gunasekaran V, Kirubakaran MG, Shastry JC. Acute eosinophilic glomerulonephritis with Bancroftian filariasis. *Postgrad Med J* **1979**; 55:905–7.
  24. Date A, Shastry JC, Johnny KV. Ultrastructural glomerular changes in filarial chyluria. *J Trop Med Hyg* **1979**; 82:150–4.
  25. Ormerod AD, Petersen J, Hussey JK, Weir J, Edward N. Immune complex glomerulonephritis and chronic anaerobic urinary infection—complications of filariasis. *Postgrad Med J* **1983**; 59:730–3.
  26. Waugh DA, Alexander JH, Ibels LS. Filial chyluria associated glomerulonephritis and therapeutic considerations in the chyluric patient. *Aust N Z J Med* **1980**; 10:559–62.
  27. Dixit V, Gupta AK, Bisen PS, Prasad GB, Harinath BC. Serum immune complexes as diagnostic and therapeutic markers in lymphatic filariasis. *J Clin Lab Anal* **2007**; 21:114–8.
  28. Awadzi K, Edwards G, Duke BO, et al. The co-administration of ivermectin and albendazole—safety, pharmacokinetics and efficacy against *Onchocerca volvulus*. *Ann Trop Med Parasitol* **2003**; 97:165–78.
  29. Na-Bangchang K, Kietinun S, Pawa KK, Hanpitakpong W, Na-Bangchang C, Lazdins J. Assessments of pharmacokinetic drug interactions and tolerability of albendazole, praziquantel and ivermectin combinations. *Trans R Soc Trop Med Hyg* **2006**; 100:335–45.
  30. Mirfazaelian A, Dadashzadeh S, Rouini MR. Effect of gender in the disposition of albendazole metabolites in humans. *Eur J Clin Pharmacol* **2002**; 58:403–8.
  31. Alvarez LI, Mottier ML, Sanchez SF, Lanusse CE. Ex vivo diffusion of albendazole and its sulfoxide metabolite into *Ascaris suum* and *Fasciola hepatica*. *Parasitol Res* **2001**; 87:929–34.
  32. Serbus LR, Landmann F, Bray WM, et al. A cell-based screen reveals that the albendazole metabolite, albendazole sulfone, targets *Wolbachia*. *PLoS Pathog* **2012**; 8:e1002922.